ICPS
2019 International Convention of Psychological Science · 2019
Effects of Opioidergic and Dopaminergic Antagonism on Facial Mimicry
- Sebastian Korb
University of Vienna - Matthäus Willeit
Department of Psychiatry and Psychotherapy (Division of General Psychiatry),Medical University of Vienna - Giorgia Silani
University of Vienna
Abstract
To investigate the neurochemical modulation of facial mimicry, healthy participants received, in a double-blind between-subjects design, 400 mg of the dopamine D2/3 receptor antagonist amisulpride, 50 mg of the opioid receptor antagonist naltrexone, or placebo. Electromyography showed reduced facial mimicry in the naltrexone group.
Social Cognition
